Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms (FODMAPendo)

Effect of FODMAP Diet on Pain, Quality of Life, and Sexual Function in Women With Pelvic Endometriosis and Gastrointestinal Symptoms: a Randomized Controlled Trial

The main objective of the study is to assess whether a dietary regimen based on the principles of the FODMAP diet, compared with the current treatment programme which does not include specific dietary recommendations, can improve pain symptoms in patients with symptomatic endometriosis and intestinal symptoms (i.e. bloating, nausea, constipation, diarrhoea and vomiting) attributable to irritable bowel syndrome, compared with a control group

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Endometriosis is defined as the presence of endometrial glands and stroma outside the uterine cavity, mostly, though not exclusively, in the pelvis. It is a chronic, estrogen-dependent inflammatory condition in which ectopic foci grow and proliferate under the action of estradiol, which plays a pro-inflammatory and anti-apoptotic role.

Pelvic pain represents the most typical manifestation of endometriosis. In particular, dysmenorrhea is the most frequent symptom.

In addition to typical gynecological symptoms, gastrointestinal symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) affect up to 90 percent of patients with endometriosis It has been reported how a diet low in oligosaccharides, disaccharides, monosaccharides, and fermentable polyols (FODMAP diet) is superior to other dietary treatments for the treatment of symptoms associated with irritable bowel syndrome.

Short-chain polysaccharides (FODMAPs) are found in a variety of fruits, vegetables and grains. FODMAPs are poorly absorbed in the gut, and are readily fermented by bacteria.

Their osmotic actions and gas production cause distention of the intestinal lumen inducing pain and bloating in patients with visceral hypersensitivity, with secondary effects on intestinal motility.

Although hormonal therapies represent the therapeutic cornerstone of endometriosis, we hypothesize that the FODMAP diet may represent a complementary and adjuvant approach for the treatment of abdominal/pelvic algic symptoms (and particularly bowel-type symptoms), resulting in significant improvement in the quality of life of affected women.

The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can improve algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome,

Eligible women will be selected among those attending the Endometriosis Clinic of the "L. Mangiagalli ", IRCCS Ca 'Granda Foundation and Ospedale Maggiore Policlinico, and will be randomized into two homogeneous groups ("intervention" and "control") (1:1): the intervention group will consist of women with symptomatic endometriosis and concomitant bowel symptoms under estro-progestin or progestin treatment, who will be asked to follow a dietary regimen based on the principles of the FODMAP diet; women in the control group will not be given specific instructions about the diet to follow.

Women will be randomized and assigned to two groups: 1) "FODMAP diet" (FD) group; 2) "usual diet" (UD) group. All patients participating in the study will undergo clinical and ultrasonographic evaluation at the beginning of the study, after 3 months and after 6 months. On these occasions, women will be routinely asked to complete some questionnaires, one on pain (a numerical rating scale, NRS), to the evaluation of gastrointestinal symptoms (NRS related to intestinal symptoms, such as abdominal bloating, nausea, constipation, diarrhea and vomiting), one on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the Hospital Anxiety and Depression scale, HADS), one on sexual functioning (theFemale Sexual Function Index, FSFI) and one on the global impression of change (Patients' Global Impression of Change scale, PGIC). Women will also be asked to rate the degree of satisfaction with their treatment.

Patients randomized into the intervention group will participate in an initial meeting with the dietitian during which they will receive targeted nutritional counseling. They will be provided with the dietary pattern to follow. Follow-up of the diet will include telephone follow-up 6 to 8 weeks after the start of the study, at 3 months and at 6 months to assess dietary adherence.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

150

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Age between 18 and 45 years
  • BMI between 18.5 and 24.9,
  • Surgical, clinical or instrumental diagnosis of endometriosis
  • Presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, on estro-progestin or progestin treatment or in the absence of hormonal treatment

Exclusion Criteria:

  • Associated conditions that may cause pelvic pain independent of the presence of endometriosis (e.g., pelvic varices and salpingitis outcomes)
  • chronic inflammatory bowel disease (Crohn's disease or ulcerative rectocolitis).
  • patients with obstructive uropathy, subocclusive intestinal stenosis
  • complex adnexal masses or typical endometriomas greater than 5 cm in diameter.
  • women who are obese (BMI ≥ 30) or underweight (BMI < 18)
  • women on vegetarian-vegan dietary regimens,
  • women with metabolic diseases that require specific dietary indications such as in the case of diabetes and celiac disease.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: FODMAP diet group
Patients randomized to the treatment arm were proposed to follow a FODMAP diet throughout the study period
Diet low in oligosaccharides, disaccharides, monosaccharides and fermentable polyols
Ingen indgriben: Usual diet group

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change of pain related syntomps in patients with bowel symptoms
Tidsramme: 6 months
The primary objective of the study is to evaluate whether a dietary regimen based on the principles of the FODMAP diet versus the current treatment program, which does not include specific dietary indications, can change algic symptoms in patients with symptomatic endometriosis and the presence of bowel symptoms (i.e., bloating, nausea, constipation, diarrhea, and vomiting) referable to irritable bowel syndrome, compared with a control group. The outcome will be measured trough Numerical Rating Scale (NRS) on dismenorrea, dyspareunia, non menstrual pelvic pain and dyschezia.
6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Gastrointestinal syntomps, patient satisfaction, health-related quality of life, psychological conditions, patient's overall condition and anthropometric parameters
Tidsramme: 6 months
  1. Assessment of patient satisfaction during treatment, measured using a five-point Likert scale
  2. Assessment of gastrointestinal symptoms (abdominal bloating, nausea, constipation, diarrhea, and vomiting) using a numerical rating scale (NRS, 0 to 10)
  3. The impact on health-related quality of life assessed using the Short-Form Health Survey 12 (SF-12)
  4. The impact on sexual function using the Female Sexual Function Index (FSFI) questionnaire
  5. The impact on patients' psychological conditions using the HADS (Hospital Anxiety and Depression Scale)
  6. The patient's overall condition using the Patients' Global Impression of Change (PGIC) scale, a seven-point scale (greatly improved, much improved, slightly improved, unchanged, slightly worsened, muc
  7. Changes in anthropometric parameters through changes in BMI and impedance analysis of body composition
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. marts 2024

Primær færdiggørelse (Anslået)

15. november 2026

Studieafslutning (Anslået)

15. december 2026

Datoer for studieregistrering

Først indsendt

10. maj 2024

Først indsendt, der opfyldte QC-kriterier

12. maj 2026

Først opslået (Faktiske)

15. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

15. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. maj 2026

Sidst verificeret

1. april 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med FODMAP diet

Abonner